

# EIP



## JIPLP: Insufficiency finally upheld as ground for invalidity of antibody claim

The Journal of Intellectual Property Law and Practice has published an article by partner Darren Smyth about the judgement in *Eli Lilly & Company v Janssen Alzheimer Immunotherapy*.

Mr Justice Arnold determines that a patent directed towards antibodies to  $\beta$ -amyloid peptide, for the treatment of Alzheimer's disease, is invalid for insufficiency.

To read the JIPLP article in full, click [here](#).